April 22 - 25
Banff, Alberta Canada
Visit our booth #6
Conference Information
Join us in Banff, Alberta for the Canadian Society for Immunology Annual Meeting.
Meet our scientists on-site and discover our universal, end-to-end spatial biology solution, answering fundamental research needs involving biomarker screening and tissue profiling.
Our solutions allow you to leverage your existing antibody library and get reproducible results while providing hyperplex capabilities for biomarker discovery.
Want to know more about our spatial biology solutions? Send us a message and secure a meeting with the team.
The Canadian Society for Immunology (CSI) is an organization that fosters and supports Immunology research throughout Canada. Founded in 1966, the society provides a focal point for Canadian Immunology by organizing an annual spring meeting that alternates between the west and the east of the country. One of the highlights of the annual meeting is the Cinader Award lecture, named in honor of Hardi Cinader, a founding member of CSI and its first president.
April 23
Poster Presentation
April 23
8:00 - 10:00 PM
Introduction:
The increased application of multiplex immunofluorescence (mIF) has accelerated the understanding of the spatial immune context of the tumor microenvironment (TME). State-of-the-art protocols remain technically challenging, subject to long manual executions and low reproducibility and transferability between different tissue types.
Methodology:
We developed and validated an Immuno-Oncology (IO) Core Panel of 13 clinically relevant biomarkers to study the TME on the COMET™ platform.
Formalin-fixed paraffin-embedded human tissue sections from tonsil and a 24-core multi-organ tissue microarray (TMA) were stained using the IO Core Panel from Lunaphore on the COMET™ platform by fully automated sequential immunofluorescence (seqIF™), which consists of cycles of staining, imaging, and elution. The panel simultaneously detects CD3, CD4, CD8, CD45, FoxP3, PD1, PD-L1, CD11c, CD20, CD56, CD68, αSMA and Ki-67 by indirect immunofluorescence using unlabeled primary antibodies and Alexa Fluor™ Plus secondary antibodies.
Results:
The 13-plex IO Core panel was developed and validated on tonsils as positive control tissue. To compare staining patterns, the sections retrieved from COMET™ after seqIF™ were stained by a histology facility with standard immunohistochemistry (IHC) established for routine pathological diagnosis. All markers demonstrate accurate detection with specific IF staining, comparable to gold standard IHC. The panel was transferred on a multi-organ TMA showing robust performance across multiple tissues. The protocol was optimized to achieve high staining quality for all 13 markers regarding signal specificity, sensitivity, ratio to background, and dynamic range. The repeatability and reproducibility of the automated IO Core Panel on the COMET™ platform were verified by day-to-day tests on one platform and among multiple platforms.
Conclusions:
Our study demonstrated the robustness of the validated IO Core Panel across multiple tissues with highly specific and reproducible results. Using standard off-the-shelf antibodies allows for future rapid expansion and customization of the panel, including additional primary antibodies to address specific scientific questions.